Cladribine: intermittent immunosuppression in MS



The next disease-modifying therapy (DMT) expected to become available in Canada is cladribine, an oral agent initially developed a decade ago (see The return of cladribine in RRMS, NeuroSens, August 23, 2017). The drug was approved by the European Medicines Agency in June, and is currently in review with Health Canada.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page